This study showed that a single time point [68Ga]Ga-PSMA-PET scan can be used to predict the absorbed dose of [177Lu]Lu-PSMA therapy to the kidney, liver, salivary glands, and (to a limited extent) to tumor lesions. Here, FOLH1 is linked to neoplasm.